1. Home
  2. ROIV vs RGEN Comparison

ROIV vs RGEN Comparison

Compare ROIV & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$21.70

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$164.53

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROIV
RGEN
Founded
2014
1981
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.1B
8.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ROIV
RGEN
Price
$21.70
$164.53
Analyst Decision
Strong Buy
Buy
Analyst Count
8
10
Target Price
$24.31
$174.90
AVG Volume (30 Days)
8.2M
583.5K
Earning Date
02-09-2026
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
$20,329,000.00
$707,890,000.00
Revenue This Year
N/A
$17.84
Revenue Next Year
$741.42
$12.44
P/E Ratio
N/A
$6,546.81
Revenue Growth
N/A
11.74
52 Week Low
$8.73
$102.97
52 Week High
$23.47
$182.52

Technical Indicators

Market Signals
Indicator
ROIV
RGEN
Relative Strength Index (RSI) 52.94 55.35
Support Level $21.36 $161.41
Resistance Level $22.72 $167.65
Average True Range (ATR) 0.80 4.45
MACD -0.13 0.06
Stochastic Oscillator 45.25 75.36

Price Performance

Historical Comparison
ROIV
RGEN

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: